Effect of PF-00734200 in Subjects With Type 2 Diabetes

Phase 2

Completed

• Conditions: Diabetes Mellitus, Type 2
• Interventions: Drug: PF-00734200 30 mg QD; Drug: Placebo; Drug: PF-00734200 20 mg QD

• Registration Number: NCT00618007
• Lead Sponsor: Pfizer

Brief Summary

To determine the effect of PF-00734200 on HbA1c in type 2 diabetic subjects receiving metformin

Detailed Description

Not available

Study Timeline

• Study Start: 2008-02
• Study First Submitted: 2008-02-05
• Study First Submitted QC: 2008-02-15
• Study First Posted: 2008-02-18
• Primary Completion: 2008-08
• Study Completion: 2008-08
• Disposition First Submitted: 2009-03-20
• Disposition First Submitted QC: 2009-09-24
• Disposition First Posted: 2009-09-28
• Status Verified: 2011-06
• Last Update Submitted: 2011-06-09
• Last Update Posted: 2011-06-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 289

Inclusion Criteria

Men or women between 18-80 years of age with poorly controlled Type 2 diabetes

Read More

Exclusion Criteria

Type 1 or secondary forms of diabetes Currently using insulin

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
30 mg QD	PF-00734200 30 mg QD	-
Placebo	Placebo	-
20 mg QD	PF-00734200 20 mg QD	-

Primary Outcome Measures

Name	Time	Method
HbA1c	12 weeks

Secondary Outcome Measures

Name	Time	Method
Fasting Glucose	12 weeks
Fasting Insulin	12 weeks

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇵🇷 San Juan, Puerto Rico